These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1336984)

  • 1. An attempt to standardize APTT reagents used to monitor heparin therapy.
    Ray M; Carroll P; Smith I; Hawson G
    Blood Coagul Fibrinolysis; 1992 Dec; 3(6):743-8. PubMed ID: 1336984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent.
    Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N
    J Thromb Haemost; 2012 Nov; 10(11):2338-43. PubMed ID: 22909048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy.
    van den Besselaar AM; Neuteboom J; Meeuwisse-Braun J; Bertina RM
    Clin Chem; 1997 Jul; 43(7):1215-22. PubMed ID: 9216459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The APTT monitoring of heparin--the ISTH/ICSH collaborative study.
    Van der Velde EA; Poller L
    Thromb Haemost; 1995 Jan; 73(1):73-81. PubMed ID: 7740500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin in vitro sensitivity of the activated partial thromboplastin time in canine plasma depends on reagent.
    Mischke R
    J Vet Diagn Invest; 2003 Nov; 15(6):588-91. PubMed ID: 14667026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of two APTT reagents which use silica activators.
    Ray MJ; Hawson GA
    Clin Lab Haematol; 1989; 11(3):221-32. PubMed ID: 2556232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT.
    D'Angelo A; Seveso MP; D'Angelo SV; Gilardoni F; Dettori AG; Bonini P
    Am J Clin Pathol; 1990 Sep; 94(3):297-306. PubMed ID: 2396604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance characteristics of a new synthetic APTT reagent.
    Ts'ao C; Neofotistos D; Oropeza M; Rogan M; Santos M
    Clin Lab Haematol; 1998 Oct; 20(5):307-13. PubMed ID: 9807679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
    Favaloro EJ; Kershaw G; Mohammed S; Lippi G
    Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.
    Okuda M; Yamamoto Y
    Clin Lab Haematol; 2004 Jun; 26(3):215-23. PubMed ID: 15163321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
    Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
    Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of calcium ions on the activated partial thromboplastin time of heparinized plasma.
    Greenberg CS; Adams JP; Mullen PE; Koepke JA
    Am J Clin Pathol; 1986 Oct; 86(4):484-9. PubMed ID: 3766461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH
    Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
    Kershaw G
    Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.